Phase 3 Trial of Tarlatamab (SC vs IV) in Extensive-Stage Small Cell Lung Cancer After Platinum Based First-line Chemotherapy (ES-SCLC)
← catalyst calendarNCT07778316 · readout in 398 d
Sponsored by Amgen (industry) · AMGN — their whole pipeline →.
Phase
Phase 3
Status
Recruiting
Study type
Interventional
Design
Randomized · None · Treatment
Enrollment
400estimated
Sites
2
Countries
China, United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-21
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2026-08-31 | estimated | When the study began enrolling |
| Primary completion | 2027-09-24 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2030-07-30 | estimated | The whole study's end, after follow-up |
| First posted | 2026-08-21 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-08-21 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Small Cell Lung Cancer
Intervention
- Drug: Tarlatamab — also filed as AMG 757, IMDELLTRA
Primary outcomes
what the primary-completion date above is the date OFArea Under the Curve From Cycle 2 Day 1 to Day 15 (AUC C2D1-D15) of Tarlatamab
measured From Cycle 2 Day 1 to Day 15 (each cycle is 28 days)
Predose Concentration (Ctrough) of Tarlatamab
measured On Cycle 2 Day 15 (each cycle is 28 days)
Permalink · AMGN's whole pipeline · Catalyst calendar · Every registered study · What changed